U.S. Markets closed

PLx Pharma Inc. (PLXP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5212-0.0222 (-4.09%)
At close: 04:00PM EDT
0.5472 +0.03 (+4.99%)
After hours: 06:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5434
Bid0.5175 x 1300
Ask0.6247 x 900
Day's Range0.5101 - 0.5505
52 Week Range0.5100 - 21.1890
Avg. Volume352,100
Market Cap14.352M
Beta (5Y Monthly)4.08
PE Ratio (TTM)N/A
EPS (TTM)-1.7450
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
  • GlobeNewswire

    Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels

    Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief Legendary Baseball Pitcher and Avid Golfer John Smoltz Uses VAZALORE 325 mg For Fast, Effective Pain Relief “From baseball to golf, I don’t want aches and pain to slow me down,” said Smoltz. “VAZALORE is the only pain reliever I have found that works quickly on my aches and pains and doesn’t upset my stomach.” SPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or t

  • Simply Wall St.

    PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k

    Insiders who acquired US$65k worth of PLx Pharma Inc.'s ( NASDAQ:PLXP ) stock at an average price of US$3.66 in the...

  • Benzinga

    PLx Pharma Looks At Alternatives As Vazalore Faces Macro Headwinds

    JMP Securities has downgraded PLx Pharma Inc (NASDAQ: PLXP) to Market Perform from Market Outperform as the company explores strategic alternatives. PLX Pharma reported 2Q FY22 financial results below expectations, primarily due to lower-than-expected Vazalore sales this quarter ($0.5 million vs. JMP/ consensus estimate of $3.3 million/$3.6 million, respectively). The management pointed to multiple macro headwinds impacting the launch, JMP writes. The company disclosed that it is exploring strat